28128970|t|Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
28128970|a|This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 report focuses primarily on the revised and novel parts of the document. The most significant changes include: (1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; (2) for each of the groups A to D, escalation strategies for pharmacologic treatments are proposed; (3) the concept of deescalation of therapy is introduced in the treatment assessment scheme; (4) nonpharmacologic therapies are comprehensively presented; and (5) the importance of comorbid conditions in managing chronic obstructive pulmonary disease is reviewed.
28128970	0	15	Global Strategy	T062	C0035171
28128970	24	33	Diagnosis	T062	C1704656
28128970	35	45	Management	T058	C0376636
28128970	51	61	Prevention	T062	C1706420
28128970	65	97	Chronic Obstructive Lung Disease	T047	C0024117
28128970	111	133	GOLD Executive Summary	T170	C0282574
28128970	139	156	Executive Summary	T170	C0282574
28128970	164	179	Global Strategy	T062	C0035171
28128970	188	197	Diagnosis	T062	C1704656
28128970	199	209	Management	T058	C0376636
28128970	215	225	Prevention	T062	C1706420
28128970	229	233	COPD	T047	C0024117
28128970	235	289	Global Initiative for Chronic Obstructive Lung Disease	T170	C0282574
28128970	291	295	GOLD	T170	C0282574
28128970	302	308	report	T170	C0684224
28128970	334	341	revised	T061	C1527075
28128970	365	373	document	T170	C1301746
28128970	396	403	changes	T169	C0392747
28128970	421	431	assessment	T058	C0220825
28128970	435	472	chronic obstructive pulmonary disease	T047	C0024117
28128970	493	501	separate	T080	C0443299
28128970	506	528	spirometric assessment	T060	C0037981
28128970	534	552	symptom evaluation	T058	C3494438
28128970	554	565	ABCD groups	T098	C1257890
28128970	589	596	derived	T080	C1441547
28128970	614	630	patient symptoms	T033	C1317600
28128970	641	651	history of	T033	C0332119
28128970	652	665	exacerbations	T033	C4086268
28128970	687	693	groups	T098	C1257890
28128970	702	712	escalation	T052	C4086266
28128970	713	723	strategies	T062	C0035171
28128970	728	741	pharmacologic	T169	C0205464
28128970	742	752	treatments	T061	C0087111
28128970	757	765	proposed	T080	C1553874
28128970	775	782	concept	T078	C0178566
28128970	786	798	deescalation	T061	C3651014
28128970	802	809	therapy	T061	C0087111
28128970	831	840	treatment	T061	C0087111
28128970	841	851	assessment	T058	C0220825
28128970	852	858	scheme	T170	C1519193
28128970	864	890	nonpharmacologic therapies	UnknownType	C0548233
28128970	911	920	presented	T078	C0449450
28128970	948	967	comorbid conditions	T033	C1275743
28128970	971	979	managing	T058	C0184516
28128970	980	1017	chronic obstructive pulmonary disease	T047	C0024117
28128970	1021	1029	reviewed	T080	C1709940